hold on there's just too much going on in Congress lmao...
Changes how Medicare pays for new cancer drugs in hospitals.
Reps. Dunn (R-FL) and Soto (D-FL), bipartisan sponsors.
In committee, no House vote yet.
This bill aims to improve access to certain cancer treatments for Medicare patients. It changes how Medicare pays hospitals for specific cancer drugs when given in outpatient settings, requiring separate payments for costly new treatments rather than bundling them. The bill was introduced by Rep. Dunn (R-FL) and Rep. Soto (D-FL) and has been referred to the House Energy and Commerce, and Ways and Means committees for review. This means it needs approval from these committees before it can be voted on by the full House.
Introduced Mar 20, 2026
This bill was introduced in the House of Representatives on March 20, 2026. It has been sent to the House Energy and Commerce Committee and the House Ways and Means Committee for consideration. For the bill to move forward, it must be approved by these committees before it can be scheduled for a vote by the full House.
If this bill becomes law, Medicare patients receiving cancer care in hospital outpatient departments might find it easier to access newer, more expensive cancer medications. Hospitals could be more willing to provide these treatments because they would receive separate payments for them, instead of having them bundled into a general service payment. This change would specifically target certain FDA-approved cancer drugs introduced since 2008 that meet specific cost criteria.
Supporters Say
Argue the bill ensures access to innovative cancer treatments for Medicare beneficiaries by reforming payment methods.
Critics Say
Might raise concerns about the overall cost impact of separate payments on the Medicare system, despite the budget neutrality clause.
Supporters of the "FAIC Act" believe it is crucial for ensuring that Medicare patients can receive the latest and most effective cancer treatments without hospitals facing financial disincentives. They emphasize that the current payment system can make it difficult for hospitals to afford and provide innovative but costly drugs. Potential critics, while not explicitly mentioned in the bill, might question how the "budget neutrality" requirement will be met and if shifting payments for specific drugs could indirectly affect other Medicare services or lead to unforeseen cost increases in the long run.